Rituximab treatment of idiopathic membranous nephropathy

This publication has 27 references indexed in Scilit:

• Anti-CD20 Therapy and Autoimmune Disease: Therapeutic opportunities and evolving insights
  Frontiers in Bioscience-Landmark, 2007
• Rituximab for Idiopathic Membranous Nephropathy
  Clinical Journal of the American Society of Nephrology, 2006
• Renal pathology in idiopathic membranous nephropathy: A new perspective
  Kidney International, 2006
• B cell depletion as a novel treatment for systemic lupus erythematosus: A phase I/II dose‐escalation trial of rituximab
  Arthritis & Rheumatism, 2004
• The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: The RENAAL Study
  Kidney International, 2003
• The relationship of FcγRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus
  Arthritis & Rheumatism, 2003
• Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion
  Annals of the Rheumatic Diseases, 2002
• Membranous nephropathy: Quo vadis?
  Kidney International, 2002
• Hapten-Induced Primary and Memory Humoral Responses Are Inhibited by the Infusion of Anti-CD20 Monoclonal Antibody (IDEC-C2B8, Rituximab)
  Clinical Immunology, 2001
• A 10-year follow-up of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy
  Kidney International, 1995